|
pubmed:abstractText |
Recent intervention trials failed to show a significant decrease in mortality of ischemic heart disease in hypertensive patients given pharmacological treatment. These results led to a reassessment of cardiovascular risks of antihypertensive drugs per se and particularly diuretics. Captopril and Enalapril, antihypertensive drugs acting as converting enzyme inhibitors, might have some theoretical advantage over other antihypertensive drugs. The chronic ACE inhibitors therapy does not compromise glucose, lipid and urate and it seems not to be persistent in long-term administration.
|
